Regulation of phage therapy medicinal products: developments, challenges, and opportunities
Open accessAbstract
Due to their biological properties, bacteriophages represent a regulatory specialty and, at the same time, a challenge with regard to medicinal product approval. Established European guidelines on pharmaceutical quality, preclinical development, and clinical development are only partially applicable. The growing threat posed by infections with multidrug-resistant bacteria has not only boosted the development of bacteriophages for the treatment of bacterial infections in recent years but has also led to substantial progress in adapting regulatory requirements. In 2024, harmonized quality criteria for phage therapy medicinal products and active substances were implemented for the first time in the European Pharmacopoeia. Future European pharmaceutical legislation and recent national acts such as the German Medical Research Act are intended to enable exemptions that address the specific characteristics of phage therapeutics and open new regulatory pathways. Increasing amounts of data on clinical use of phage therapeutics are being published; however, the anticipated breakthrough in the form of a demonstration of efficacy in randomized controlled clinical trials has not yet been achieved. Growing experience with innovative phage preparations has been utilized to adjust regulatory requirements. On the path to approval of a defined phage therapy medicinal product, the evidence-based demonstration of efficacy and safety in randomized controlled clinical trials is the next and decisive step.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Development and implementation of comprehensive regulatory standards for phage-based therapies remain an evolving challenge in the field.
“Development and implementation of comprehensive regulatory standards for phage-based therapies remain an evolving challenge in the field [159,160]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Clokie, M. R. J., Millard, A. D., Letarov, A. V., & Heaphy, S. (2011) · Bacteriophage · doi:10.4161/bact.1.1.14942 · Cited by 1,154 · see citing works
Jault, P., Leclerc, T., Jennes, S., Pirnay, J., Que, Y., Resch, G., Rousseau, A., Ravat, F., Carsin, H., Floch, R. L., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30482-1 · Cited by 878 · see citing works
Wright, A., Hawkins, C., Änggård, E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 869 · see citing works
Phage therapy: From biological mechanisms to future directions
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023) · Cell · doi:10.1016/j.cell.2022.11.017 · Cited by 817 · see citing works
A century of the phage: past, present and future
Salmond, G. P. C., & Fineran, P. C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3564 · Cited by 816 · see citing works
Sarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., Bourdin, G., McCallin, S. E., Ngom‐Bru, C., Neville, T., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.023 · Cited by 543 · see citing works
Pirnay, J., Djebara, S., Steurs, G., Griselain, J., Cochez, C., Soir, S. D., Glonti, T., Spiessens, A., Berghe, E. V., Green, S. I., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01705-x · Cited by 502 · see citing works
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial
Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., Wolcott, B. M., Ward, L. S., & Sulakvelidze, A. (2009) · Journal of Wound Care · doi:10.12968/jowc.2009.18.6.42801 · Cited by 468 · see citing works
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review
Uyttebroek, S., Chen, B., Onsea, J., Ruythooren, F., Debaveye, Y. A., Devolder, D., Spriet, I., Depypere, M., Wagemans, J., Lavigne, R., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00612-5 · Cited by 435 · see citing works
Liu, C. G., Green, S. I., Min, L., Clark, J. R., Salazar, K. C., Terwilliger, A. L., Kaplan, H. B., Trautner, B. W., Ramig, R. F., & Maresso, A. W. (2020) · mBio · doi:10.1128/mbio.01462-20 · Cited by 411 · see citing works
Leitner, L., Ujmajuridze, A., Чанішвілі, Н., Goderdzishvili, M., Chkonia, I., Rigvava, S., Chkhotua, A. B., Changashvili, G., McCallin, S. E., Schneider, M. P., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30330-3 · Cited by 325 · see citing works
The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies
Liu, D., Belleghem, J. D. V., de Vries, C. R., Burgener, E. B., Chen, Q., Manasherob, R., Aronson, J., Amanatullah, D. F., Tamma, P. D., & Suh, G. A. (2021) · Viruses · doi:10.3390/v13071268 · Cited by 273 · see citing works
Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals
Payne, R. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109520 · Cited by 214 · see citing works
Dedrick, R. M., Freeman, K. G., Nguyen, J. A., Bahadirli-Talbott, A., Smith, B. E., Wu, A. E., Ong, A., Lin, C. T., Ruppel, L. C., Parrish, N. M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01403-9 · Cited by 201 · see citing works
Contribution of the Immune Response to Phage Therapy
Krut, O., & Bekeredjian‐Ding, I. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701745 · Cited by 173 · see citing works
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation
Nang, S. C., Lin, Y., Fabijan, A. P., Chang, R. Y. K., Rao, G. G., Iredell, J. R., Chan, H., & Li, J. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.01.021 · Cited by 170 · see citing works
Palma, M., & Qi, B. (2024) · Infectious Disease Reports · doi:10.3390/idr16060092 · Cited by 114 · see citing works
Phage Therapy: The Pharmacology of Antibacterial Viruses
Danis-Wlodarczyk, K. M., Dąbrowska, K., & Abedon, S. T. (2020) · Current Issues in Molecular Biology · doi:10.21775/cimb.040.081 · Cited by 88 · see citing works
Improving phage therapy by evasion of phage resistance mechanisms
Bleriot, I., Pacios, O., Blasco, L., Fernández-García, L., López, M. C., Ortiz-Cartagena, C., Barrio-Pujante, A., García‐Contreras, R., Pirnay, J., Wood, T. K., et al. (2023) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae017 · Cited by 67 · see citing works
Doub, J. B. (2020) · Antibiotics · doi:10.3390/antibiotics9110799 · Cited by 45 · see citing works
Karn, S. L., Bhartiya, S. K., Pratap, A., Saroj, S. K., Kumar, R., Sahu, M., Gangwar, M., & Nath, G. (2024) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346231226342 · Cited by 30 · see citing works
Ngiam, L., Weynberg, K. D., & Guo, J. (2024) · ISME Communications · doi:10.1093/ismeco/ycae082 · Cited by 21 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Summers W. C. (1999). Félix d’Herelle and the origins of molecular biology (New Haven: Yale University Press).
- Weiner I. Kahan-Hanum M. Buchstab N. Zelcbuch L. Navok S. Sherman I.. (2025). Phage therapy with nebulized cocktail BX004 – A for chronic Pseucomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial. Nat. Commun. 16, 5579. doi: 10.1177/15347346231226342, PMID: 40593506 PMC12216271 · DOI
Cited by
Sorted by citations
Formulating and stabilising therapeutic phages: A review
Siafakas, E., Duong, H. T. T., & Iredell, J. R. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107759 · Cited by 6 · see citing works
Phage therapy in oncology: opportunities for cancer prevention and treatment
Mutalik, V. K., Inman, J. L., Chang, H., Arkin, A., & Mao, J.-H. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.02.001 · Cited by 5 · see citing works
Lipopolysaccharide-targeting treatments for multidrug-resistant Pseudomonas aeruginosa
Wang, M. C., & Kirienko, N. V. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639679 · Cited by 5 · see citing works
Fortaleza, J. A. G., Cabuhat, K. S. P., Lagunzad, H. C., Panizales, W. B., Cruz, Matamis, J. G., Mamaat, J. E. R., Libres, A. C., Dulay, R. M. R., & Nuevo, J. J. M. (2026) · Antibiotics · doi:10.3390/antibiotics15070635 · Cited by 3 · see citing works
Li, L., Feng, L., Li, Q., Zhou, Y., Liu, S., Song, H., Kang, S., Chen, H., Cong, H., & Liu, S. (2026) · Microbial Biotechnology · doi:10.1111/1751-7915.70330 · Cited by 2 · see citing works
Alshehri, A. A., Aodah, A. H., Alradwan, I. A., Alnefaie, M. K., Nassar, M. S., Alduhaymi, I. S., Aldossary, A. M., Fayez, N. A., Tawfik, E. A., & Almughem, F. A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030387 · Cited by 2 · see citing works
Ferraz, M. P. (2026) · Applied Sciences · doi:10.3390/app16042002 · Cited by 1 · see citing works
Dahiya, S., Sharma, N., & Nehra, K. (2026) · Discover Viruses. · doi:10.1007/s44370-026-00048-x · Cited by 1 · see citing works
Omosigho, P. O., Famuwagun, T. S., & Okesanya, O. J. (2026) · Exploration of Medicine · doi:10.37349/emed.2026.1001422 · Cited by 1 · see citing works
Bacteriophage-based control of Pseudomonas spp.: research trends and biotechnological challenges
Bolsan, A. C., Terrabuio, A. M., Edwiges, T., Prá, M. C. D., & Gabiatti, N. C. (2026) · Folia Microbiologica · doi:10.1007/s12223-026-01458-6 · Cited by 1 · see citing works
Phage Therapy in Aquaculture: Mechanisms, Applications and Future Directions
Dewan, A., & Goulart, D. B. (2026) · Journal of Fish Diseases · doi:10.1111/jfd.70246 · Cited by 1 · see citing works
Bacteriophage Therapy: a review and the Portuguese landscape
Alves, J., Carvalho, A. C., Capela, C., Faria, B., Leite, R. D. S. C., Meneses, L., Pires, D. P., & Azeredo, J. (2026) · Revista Portuguesa de Doenças Infecciosas (RPDI) · doi:10.65332/rpdi.v20.140
Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects
Li, X., Yao, S., & Huang, G. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1846582
Microbiotherapy: an emerging adjunct for burn wound healing
Zhang, J., Zhang, K., Wang, Y., Fan, G., Lv, Y., & Ma, J. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1873498
From resistance mechanisms to therapy: Antimicrobial resistance in Gram-negative bacteria
Lee, M. (2026) · The Journal of Microbiology · doi:10.71150/jm.2604017
Giju, J. K., Padmakumar, S., Jaykumar, A. P., Babu, P., Madhavan, A., Nair, B. G., & Kumar, G. B. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1913201
Kumar, R. R., Kumari, G., Majhi, S., & Kumar, S. (2026) · doi:10.67796/jph.v1i1.10
Irbaz, M., Hamood, Z., Shahid, S., Ghufran, A., Ajmal, A., & Rafiq, I. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-05134-8
Михайлович, З. Ф. (2026) · Viruses · doi:10.3390/v18080907
Bacteriophages as emerging modulators of antitumor immunity in the tumor microenvironment
Chen, X., Zhang, J., Gao, F., & Du, H. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128700
Watts, K., Lin, R. C. Y., Lynch, S. A., Warning, J., Barr, J. J., Zakour, N. L. B., Campbell, A. J., Chan, J., Collie, L., Hedges, M. G., et al. (2026) · medRxiv · doi:10.64898/2026.08.26.26361487
Bian, Y., Lou, J., Zhang, H., Xu, H., Zhang, L., & Liu, Y. (2026) · Veterinary Microbiology · doi:10.1016/j.vetmic.2026.111209
Tabassum, N., Javaid, A., Karthikeyan, A., Kim, M., Kim, Y., & Khan, F. (2026) · Antibiotics · doi:10.3390/antibiotics15090874
AL-Khfaji, K. M. S., AL-MOUSAWY, J. M., Al-Juhaishi, A. M. R., Khadim, F. T., Jasim, G. N., & Radhi, F. A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108942
Ang, M. Y., Chen, L., Song, L., Lipovich, L., & Choo, S. W. (2026) · Pharmaceuticals · doi:10.3390/ph19091465
Avanigadda, B. V., Venigalla, R. K., Ede, R., Jetti, P. R., Kandi, V., & Suvvari, T. K. (2026) · Cureus · doi:10.7759/cureus.116535
Touati, A., Kirat, H., & Bellil, Z. (2026) · Microbiology Research · doi:10.3390/microbiolres17100191
Khan, S., Ilyas, N., Nawaz, A., Nawaz, H., Khan, M. I., Bhatti, M. T., Hussain, U., & Khan, S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12793-9
Bahati, S. Y., & Maghembe, R. S. (2026) · Bacteriophage · doi:10.1016/j.phage.2026.100014
Engineering phage therapeutics with intrinsic biocontainment
Czernuszka, M. R., Hoffmann, S. A., Brockhurst, M. A., & Cai, Y. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.09.010
Jalili, M., Saffari, M., & Jalilian, F. A. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2746044
Nautiyal, D., Sahu, M. S., & Jain, U. (2026) · Future Microbiology · doi:10.1080/17460913.2026.2752147
Shamsuzzaman, M., Konika, T. A., Hasan, M. N., Ahamed, S., Kim, S., Choi, Y.-J., & Kim, J. (2026) · Bacteriophage · doi:10.1016/j.phage.2026.100018
- Authors
- Fuerst-Wilmes, M., Respondek, V., Schramm, M., Lilienthal, N., Buss, K., & Duechting, A.
- Affiliations
- Federal Institute for Drugs and Medical Devices (DE)
- Corresponding author
- Duechting, Anja
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2025-10-29
- Volume
- 15
- Pages
- 1631359-1631359
- ISSN
- 2235-2988 (ISSN-L)
- PMC
- PMC12605122
- OpenAlex
- W4415650569
- Cited by
- 31
- References
- 22
- Citations by year
- 2026: 31
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Environmental Science › Ecology › Bacteriophages and microbial interactions
- Health Sciences › Medicine › Physiology › Biomedical Ethics and Regulation
- Health Sciences › Health Professions › Health Information Management › Healthcare Regulation
- Keywords
- phage therapy, bacteriophages, regulatory approval, European Pharmacopoeia, quality standards, regulatory exemptions, multidrug-resistant bacteria, clinical trials, pharmaceutical law
- MeSH terms
- Phage Therapy, Bacterial Infections, Bacteriophages, Europe, Humans, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
